THE POSSIBILITIES OF USING A NEW FIXED-DOSE COMBINATION OF ROSUVASTATIN AND ACETYLSALICYLIC ACID: FOCUS GROUPS OF PATIENTS
The review focuses on the impairment of the carotid, coronary arteries and lower-extremity arterial disease. Systemic involvement of various vascular beds in atherogenesis is emphasized. Epidemiological characteristics of morbidity and mortality from the main clinical manifestations of atheroscleros...
Saved in:
| Main Authors: | O. D. Ostroumova, A. I. Kochetkov, N. Yu. Voevodina, S. S. Sharonova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2018-07-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/1699 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Multiply doses of FDC of rosuvastatin and ezetimibe versus rosuvastatin monotherapy in Chinese patients with hypercholesterolemia (ROSE-CH): multicenter, randomized-controlled trial
by: Xianyou Ji, et al.
Published: (2025-07-01) -
Effectiveness of fixed-dose combination of rosuvastatin and ezetimibe in heterozygous familial hypercholesterolemia from the RENAISSANCE registry
by: I. A. Alekseeva, et al.
Published: (2025-08-01) -
PREDICTION OF THE INFLUENCE OF ORIGINAL AND GENERIC ROSUVASTATIN ON DIRECT MEDICAL COSTS OF SECONDARY PREVENTION IN PATIENTS WITH CHRONIC TYPES OF ISCHEMIC HEART DISEASE
by: E. I. Tarlovskaya, et al.
Published: (2015-08-01) -
Rosuvastatin-based combination treatment with acetylsalicylic acid or ezetimibe in the management of patients at high and very high cardiovascular risk. Expert opinion paper of the Polish Lipid Association 2025
by: Maciej Banach, et al.
Published: (2025-01-01) -
ROSUVASTATIN - THE MOST POTENT STATIN IN CARDIOVASCULAR DISEASE PREVENTION
by: A. E. Semenova, et al.
Published: (2018-06-01)